Daiwa Securities Group Inc. Supernus Pharmaceuticals, Inc. Transaction History
Daiwa Securities Group Inc.
- $18.8 Billion
- Q2 2024
A detailed history of Daiwa Securities Group Inc. transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Daiwa Securities Group Inc. holds 157 shares of SUPN stock, worth $4,895. This represents 0.0% of its overall portfolio holdings.
Number of Shares
157
Previous 217
27.65%
Holding current value
$4,895
Previous $7,000
42.86%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding SUPN
# of Institutions
255Shares Held
59.2MCall Options Held
47.9KPut Options Held
13.1K-
Black Rock Inc. New York, NY10.4MShares$324 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.14MShares$191 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY5.27MShares$164 Million1.83% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.87MShares$89.4 Million0.02% of portfolio
-
Macquarie Group LTD Australia, C32.68MShares$83.6 Million0.08% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $1.67B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...